In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model

Toxicology and Applied Pharmacology

Volumn 322, Issue , 2017, Pages 60-74

  Sirenko, Oksana ^a   Grimm, Fabian A ^b   Ryan, Kristen R ^c   Iwata, Yasuhiro ^b   Chiu, Weihsueh A ^b   Parham, Frederick ^c   Wignall, Jessica A ^d   Anson, Blake ^e   Cromwell, Evan F ^f   Behl, Mamta ^c   Rusyn, Ivan ^b   Tice, Raymond R ^c  

^a MOLECULAR DEVICES CORPORATION   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d ICF INTERNATIONAL   (United States)

^e Cellular Dynamics International   (United States)

^f Protein Fluidics Inc   (United States)

Author keywords

Alternative methods; Cardiomyocytes; Cardiotoxicity; Environmental toxicology; High content screening; Induced pluripotent stem cells

Indexed keywords

CALCIUM ION; ENVIRONMENTAL CHEMICAL; FLAME RETARDANT; HOE 33342; PESTICIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; CARDIOTOXIN; POLLUTANT;

ARTICLE; BLOOD LEVEL; CALCEIN-AM ASSAY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOTOXICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; ENVIRONMENTAL EXPOSURE; FEASIBILITY STUDY; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; MITOCHONDRIAL TOXICITY; CARDIAC MUSCLE CELL; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; POLLUTANT; TOXICITY;

CARDIOTOXINS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; ORGAN CULTURE TECHNIQUES;

EID: 85015061049     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2017.02.020     Document Type: Article

References (76)

1. Acimovic, I., Vilotic, A., Pesl, M., Lacampagne, A., Dvorak, P., Rotrekl, V., Meli, A.C., Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools. Biomed. Res. Int., 2014, 2014, 512831.
2. Anson, B.D., Kolaja, K.L., Kamp, T.J., Opportunities for use of human ips cells in predictive toxicology. Clin. Pharmacol. Ther. 89 (2011), 754–758.
3. Berridge, B.R., Hoffmann, P., Turk, J.R., Sellke, F., Gintant, G., Hirkaler, G., Dreher, K., Schultze, A.E., Walker, D., Edmunds, N., Halpern, W., Falls, J., Sanders, M., Pettit, S.D., Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities. Regul. Toxicol. Pharmacol. 65 (2013), 38–46.
4. Billiard, S.M., Timme-Laragy, A.R., Wassenberg, D.M., Cockman, C., Di Giulio, R.T., The role of the aryl hydrocarbon receptor pathway in mediating synergistic developmental toxicity of polycyclic aromatic hydrocarbons to zebrafish. Toxicol. Sci. 92 (2006), 526–536.
5. Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M.P., Zamora, V., Smith, G., Crumb, W.J., Pang, L., Lyn-Cook, B., Ross, J., Brock, M., Chvatal, S., Millard, D., Galeotti, L., Stockbridge, N., Strauss, D.G., Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias. Toxicol. Sci. 155 (2017), 234–247.
6. Bovo, E., Lipsius, S.L., Zima, A.V., Reactive oxygen species contribute to the development of arrhythmogenic Ca(2)(+) waves during beta-adrenergic receptor stimulation in rabbit cardiomyocytes. J. Physiol. 590 (2012), 3291–3304.
7. Burstyn, I., Kromhout, H., Partanen, T., Svane, O., Langard, S., Ahrens, W., Kauppinen, T., Stucker, I., Shaham, J., Heederik, D., Ferro, G., Heikkila, P., Hooiveld, M., Johansen, C., Randem, B.G., Boffetta, P., Polycyclic aromatic hydrocarbons and fatal ischemic heart disease. Epidemiology 16 (2005), 744–750.
8. Chen-Izu, Y., Xiao, R.P., Izu, L.T., Cheng, H., Kuschel, M., Spurgeon, H., Lakatta, E.G., G(i)-dependent localization of beta(2)-adrenergic receptor signaling to l-type Ca(2 +) channels. Biophys. J. 79 (2000), 2547–2556.
9. Chen, I.Y., Matsa, E., Wu, J.C., Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat. Rev. Cardiol. 13 (2016), 333–349.
10. Collins, F.S., Gray, G.M., Bucher, J.R., Toxicology. Transforming environmental health protection. Science 319 (2008), 906–907.
11. Dolman, N.J., Chambers, K.M., Mandavilli, B., Batchelor, R.H., Janes, M.S., Tools and techniques to measure mitophagy using fluorescence microscopy. Autophagy 9 (2013), 1653–1662.
12. Drawnel, F.M., Boccardo, S., Prummer, M., Delobel, F., Graff, A., Weber, M., Gerard, R., Badi, L., Kam-Thong, T., Bu, L., Jiang, X., Hoflack, J.C., Kiialainen, A., Jeworutzki, E., Aoyama, N., Carlson, C., Burcin, M., Gromo, G., Boehringer, M., Stahlberg, H., Hall, B.J., Magnone, M.C., Kolaja, K., Chien, K.R., Bailly, J., Iacone, R., Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 9 (2014), 810–821.
13. Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O., Popescu, L.M., Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J. Cell. Mol. Med. 15 (2011), 2539–2551.
14. Grimm, F.A., Iwata, Y., Sirenko, O., Bittner, M., Rusyn, I., High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes. Assay Drug Dev. Technol. 13 (2015), 529–546.
15. Grimm, F.A., Iwata, Y., Sirenko, O., Chappell, G.A., Wright, F.A., Reif, D.M., Braisted, J., Gerhold, D.L., Yeakley, J.M., Shepard, P., Seligmann, B., Roy, T., Boogaard, P.J., Ketelslegers, H.B., Rohde, A.M., Rusyn, I., A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. Green Chem. 18 (2016), 4407–4419.
16. Guo, L., Abrams, R.M., Babiarz, J.E., Cohen, J.D., Kameoka, S., Sanders, M.J., Chiao, E., Kolaja, K.L., Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123 (2011), 281–289.
17. Guo, L., Coyle, L., Abrams, R.M., Kemper, R., Chiao, E.T., Kolaja, K.L., Refining the human ipsc-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 136 (2013), 581–594.
18. Fossa, A.A., Carlson, G.P., Antiarrhythmic effect of disulfiram in various cardiotoxic models. Pharmacology 26:3 (1983), 164–171.
19. Hancox, J.C., McPate, M.J., El Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119 (2008), 118–132.
20. 2+ signaling in neuroendocrine cells (PC12). Aquat. Toxicol. 76 (2006), 37–45.
21. Herman, E.H., Ferrans, V.J., Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin. Oncol. 25 (1998), 15–21.
22. Hoekstra, M., Mummery, C.L., Wilde, A.A., Bezzina, C.R., Verkerk, A.O., Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front. Physiol., 3, 2012, 346.
23. Jang, Y., Lee, A.Y., Jeong, S.H., Park, K.H., Paik, M.K., Cho, N.J., Kim, J.E., Cho, M.H., Chlorpyrifos induces nlrp3 inflammasome and pyroptosis/apoptosis via mitochondrial oxidative stress in human keratinocyte hacat cells. Toxicology 338 (2015), 37–46.
24. Jeyaraj, D., Haldar, S.M., Wan, X., McCauley, M.D., Ripperger, J.A., Hu, K., Lu, Y., Eapen, B.L., Sharma, N., Ficker, E., Cutler, M.J., Gulick, J., Sanbe, A., Robbins, J., Demolombe, S., Kondratov, R.V., Shea, S.A., Albrecht, U., Wehrens, X.H., Rosenbaum, D.S., Jain, M.K., Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 483 (2012), 96–99.
25. Judson, R., Richard, A., Dix, D.J., Houck, K., Martin, M., Kavlock, R., Dellarco, V., Henry, T., Holderman, T., Sayre, P., Tan, S., Carpenter, T., Smith, E., The toxicity data landscape for environmental chemicals. Environ. Health Perspect. 117 (2009), 685–695.
26. Judson, R., Houck, K., Martin, M., Richard, A.M., Knudsen, T.B., Shah, I., Little, S., Wambaugh, J., Woodrow Setzer, R., Kothya, P., Phuong, J., Filer, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer, N., Sipes, N., Xia, M., Huang, R., Crofton, K., Thomas, R.S., Editor's highlight: analysis of the effects of cell stress and cytotoxicity on in vitro assay activity across a diverse chemical and assay space. Toxicol. Sci. 152 (2016), 323–339.
27. Judson, R.S., Houck, K.A., Kavlock, R.J., Knudsen, T.B., Martin, M.T., Mortensen, H.M., Reif, D.M., Rotroff, D.M., Shah, I., Richard, A.M., Dix, D.J., In vitro screening of environmental chemicals for targeted testing prioritization: the toxcast project. Environ. Health Perspect. 118 (2010), 485–492.
28. Kamakura, T., Makiyama, T., Sasaki, K., Yoshida, Y., Wuriyanghai, Y., Chen, J., Hattori, T., Ohno, S., Kita, T., Horie, M., Yamanaka, S., Kimura, T., Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ. J. 77 (2013), 1307–1314.
29. Kamiya, K., Niwa, R., Mitcheson, J.S., Sanguinetti, M.C., Molecular determinants of herg channel block. Mol. Pharmacol. 69 (2006), 1709–1716.
30. Karakikes, I., Ameen, M., Termglinchan, V., Wu, J.C., Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ. Res. 117 (2015), 80–88.
31. Kaufman, J.D., Morgan, M.S., Marks, M.L., Greene, H.L., Rosenstock, L., A study of the cardiac effects of bromochlorodifluoromethane (Halon 1211) exposure during exercise. Am. J. Ind. Med. 21 (1992), 223–233.
32. Knollmann, B.C., Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model?. Circ. Res. 112 (2013), 969–976 (discussion 976).
33. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., Pirmohamed, M., Pollard, C., Radford, J., Roome, N., Sager, P., Singh, S., Suter, T., Suter, W., Trafford, A., Volders, P., Wallis, R., Weaver, R., York, M., Valentin, J., How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 163 (2011), 675–693.
34. Lema, S.C., Schultz, I.R., Scholz, N.L., Incardona, J.P., Swanson, P., Neural defects and cardiac arrhythmia in fish larvae following embryonic exposure to 2,2′,4,4′-tetrabromodiphenyl ether (PBDE 47). Aquat. Toxicol. 82 (2007), 296–307.
35. Li, B.X., Yang, B.F., Zhou, J., Xu, C.Q., Li, Y.R., Inhibitory effects of berberine on IK1, IK, and hERG channels of cardiac myocytes. Acta Pharmacol. Sin. 22 (2001), 125–131.
36. Li, X., Nooh, M.M., Bahouth, S.W., Role of AKAP79/150 protein in beta1-adrenergic receptor trafficking and signaling in mammalian cells. J. Biol. Chem. 288 (2013), 33797–33812.
37. Lin, Z., Will, Y., Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol. Sci. 126 (2012), 114–127.
38. Liu, M., Liu, H., Dudley, S.C. Jr., Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circ. Res. 107 (2010), 967–974.
39. Lundy, S.D., Zhu, W.Z., Regnier, M., Laflamme, M.A., Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 22 (2013), 1991–2002.
40. Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja, K.L., Swanson, B.J., January, C.T., High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H2006–H2017.
41. Mansouri, K., Abdelaziz, A., Rybacka, A., Roncaglioni, A., Tropsha, A., Varnek, A., Zakharov, A., Worth, A., Richard, A.M., Grulke, C.M., Trisciuzzi, D., Fourches, D., Horvath, D., Benfenati, E., Muratov, E., Wedebye, E.B., Grisoni, F., Mangiatordi, G.F., Incisivo, G.M., Hong, H., Ng, H.W., Tetko, I.V., Balabin, I., Kancherla, J., Shen, J., Burton, J., Nicklaus, M., Cassotti, M., Nikolov, N.G., Nicolotti, O., Andersson, P.L., Zang, Q., Politi, R., Beger, R.D., Todeschini, R., Huang, R., Farag, S., Rosenberg, S.A., Slavov, S., Hu, X., Judson, R.S., Cerapp: Collaborative estrogen receptor activity prediction project. Environ. Health Perspect. 124 (2016), 1023–1033.
42. Martínez, C., Sánchez, M., Hidalgo, A., García de Boto, M.J., Involvement of K(ATP) channels in diethylstilbestrol-induced relaxation in rat aorta. Eur J Pharmacol. 413:1 (2001), 109–116.
43. Mercola, M., Colas, A., Willems, E., Induced pluripotent stem cells in cardiovascular drug discovery. Circ. Res. 112 (2013), 534–548.
44. Monge, P., Partanen, T., Wesseling, C., Bravo, V., Ruepert, C., Burstyn, I., Assessment of pesticide exposure in the agricultural population of Costa Rica. Ann. Occup. Hyg. 49 (2005), 375–384.
45. Mordwinkin, N.M., Burridge, P.W., Wu, J.C., A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J. Cardiovasc. Transl. Res. 6 (2013), 22–30.
46. Nadanaciva, S., Will, Y., Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry. Curr. Drug Targets 12 (2011), 774–782.
47. Narahashi, T., Neuronal ion channels as the target sites of insecticides. Pharmacol. Toxicol. 79 (1996), 1–14.
48. Ogata, N., Vogel, S.M., Narahashi, T., Lindane but not deltamethrin blocks a component of GABA-activated chloride channels. FASEB J. 2 (1988), 2895–2900.
49. Pearce, R.G., Setzer, R.W., Strope, C.L., Sipes, N.S., Wambaugh, J.F., Httk: R package for high-throughput toxicokinetics. J. Stat. Softw., 2017 (In press).
50. Pierson, J.B., Berridge, B.R., Brooks, M.B., Dreher, K., Koerner, J., Schultze, A.E., Sarazan, R.D., Valentin, J.P., Vargas, H.M., Pettit, S.D., A public-private consortium advances cardiac safety evaluation: achievements of the HESI cardiac safety technical committee. J. Pharmacol. Toxicol. Methods 68 (2013), 7–12.
51. Pruss-Ustun, A., Corvalan, C., Preventing Disease Through Healthy Environments: Towards an Estimate of the Environmental Burden of Disease. 2006, World Health Organization, Geneva, Switzerland.
52. Puga, A., Ma, C., Marlowe, J.L., The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem. Pharmacol. 77 (2009), 713–722.
53. Reif, D.M., Sypa, M., Lock, E.F., Wright, F.A., Wilson, A., Cathey, T., Judson, R.R., Rusyn, I., ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics 29 (2013), 402–403.
54. Roberts, R.A., Kavanagh, S.L., Mellor, H.R., Pollard, C.E., Robinson, S., Platz, S.J., Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discov. Today 19 (2014), 341–347.
55. Ryan, K.R., Sirenko, O., Parham, F., Hsieh, J.H., Cromwell, E.F., Tice, R.R., Behl, M., Neurite outgrowth in human induced pluripotent stem cell-derived neurons as a high-throughput screen for developmental neurotoxicity or neurotoxicity. Neurotoxicology 53 (2016), 271–281.
56. Sanguinetti, M.C., Tristani-Firouzi, M., hERG potassium channels and cardiac arrhythmia. Nature 440 (2006), 463–469.
57. Shah, I., Setzer, R.W., Jack, J., Houck, K.A., Judson, R.S., Knudsen, T.B., Liu, J., Martin, M.T., Reif, D.M., Richard, A.M., Thomas, R.S., Crofton, K.M., Dix, D.J., Kavlock, R.J., Using ToxCast data to reconstruct dynamic cell state trajectories and estimate toxicological points of departure. Environ. Health Perspect. 124 (2016), 910–919.
58. Sinnecker, D., Laugwitz, K.L., Moretti, A., Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. Pharmacol. Ther. 143 (2014), 246–252.
59. Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y.W., Funes, C., Rusyn, I., Anson, B., Cromwell, E.F., Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 18 (2013), 39–53.
60. Sirenko, O., Cromwell, E.F., Crittenden, C., Wignall, J.A., Wright, F.A., Rusyn, I., Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 273 (2013), 500–507.
61. Steinbeck, C., Han, Y., Kuhn, S., Horlacher, O., Luttmann, E., Willighagen, E., The chemistry development kit (CDK): an open-source java library for chemo- and bioinformatics. J. Chem. Inf. Comput. Sci. 43 (2003), 493–500.
62. Suter-Dick, L., Alves, P.M., Blaauboer, B.J., Bremm, K.D., Brito, C., Coecke, S., Flick, B., Fowler, P., Hescheler, J., Ingelman-Sundberg, M., Jennings, P., Kelm, J.M., Manou, I., Mistry, P., Moretto, A., Roth, A., Stedman, D., van de Water, B., Beilmann, M., Stem cell-derived systems in toxicology assessment. Stem Cells Dev. 24 (2015), 1284–1296.
63. Thomas, R.S., Philbert, M.A., Auerbach, S.S., Wetmore, B.A., Devito, M.J., Cote, I., Rowlands, J.C., Whelan, M.P., Hays, S.M., Andersen, M.E., Meek, M.E., Reiter, L.W., Lambert, J.C., Clewell, H.J. 3rd, Stephens, M.L., Zhao, Q.J., Wesselkamper, S.C., Flowers, L., Carney, E.W., Pastoor, T.P., Petersen, D.D., Yauk, C.L., Nong, A., Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 136 (2013), 4–18.
64. Tice, R.R., Austin, C.P., Kavlock, R.J., Bucher, J.R., Improving the human hazard characterization of chemicals: a Tox21 update. Environ. Health Perspect. 121 (2013), 756–765.
65. U.S. EPA, Benchmark dose technical guidance. Risk Assessment Forum, 2012, US EPA, Washington, DC.
66. Vogel, S., Sperelakis, N., Valinomycin blockade of myocardial slow channels is reversed by high glucose. Am. J. Phys. 235 (1978), H46–H51.
67. Wambaugh, J.F., Wetmore, B.A., Pearce, R., Strope, C., Goldsmith, R., Sluka, J.P., Sedykh, A., Tropsha, A., Bosgra, S., Shah, I., Judson, R., Thomas, R.S., Setzer, R.W., Toxicokinetic triage for environmental chemicals. Toxicol. Sci. 147 (2015), 55–67.
68. Wang, G., McCain, M.L., Yang, L., He, A., Pasqualini, F.S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., Geva, J., Roberts, A.E., Ma, Q., Ding, J., Chen, J., Wang, D.Z., Li, K., Wang, J., Wanders, R.J., Kulik, W., Vaz, F.M., Laflamme, M.A., Murry, C.E., Chien, K.R., Kelley, R.I., Church, G.M., Parker, K.K., Pu, W.T., Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20 (2014), 616–623.
69. Wetmore, B.A., Wambaugh, J.F., Ferguson, S.S., Sochaski, M.A., Rotroff, D.M., Freeman, K., Clewell, H.J. 3rd, Dix, D.J., Andersen, M.E., Houck, K.A., Allen, B., Judson, R.S., Singh, R., Kavlock, R.J., Richard, A.M., Thomas, R.S., Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125 (2012), 157–174.
70. Wetmore, B.A., Wambaugh, J.F., Ferguson, S.S., Li, L., Clewell, H.J. 3rd, Judson, R.S., Freeman, K., Bao, W., Sochaski, M.A., Chu, T.M., Black, M.B., Healy, E., Allen, B., Andersen, M.E., Wolfinger, R.D., Thomas, R.S., Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol. Sci. 132 (2013), 327–346.
71. Wetmore, B.A., Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology 332 (2015), 94–101.
72. Wetmore, B.A., Wambaugh, J.F., Allen, B., Ferguson, S.S., Sochaski, M.A., Setzer, R.W., Houck, K.A., Strope, C.L., Cantwell, K., Judson, R.S., LeCluyse, E., Clewell, H.J., Thomas, R.S., Andersen, M.E., Incorporating high-throughput exposure predictions with dosimetry-adjusted in vitro bioactivity to inform chemical toxicity testing. Toxicol. Sci. 148 (2015), 121–136.
73. Yan, M., Zhang, K., Shi, Y., Feng, L., Lv, L., Li, B., Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency. Drug Des. Devel. Ther. 9 (2015), 5737–5747.
74. Zafiropoulos, A., Tsarouhas, K., Tsitsimpikou, C., Fragkiadaki, P., Germanakis, I., Tsardi, M., Maravgakis, G., Goutzourelas, N., Vasilaki, F., Kouretas, D., Hayes, A., Tsatsakis, A., Cardiotoxicity in rabbits after a low-level exposure to diazinon, propoxur, and chlorpyrifos. Hum. Exp. Toxicol. 33 (2014), 1241–1252.
75. Zhang, Y., Huang, L., Zuo, Z., Chen, Y., Wang, C., Phenanthrene exposure causes cardiac arrhythmia in embryonic zebrafish via perturbing calcium handling. Aquat. Toxicol. 142-143 (2013), 26–32.
76. Zou, C., Kou, R., Gao, Y., Xie, K., Song, F., Activation of mitochondria-mediated apoptotic pathway in tri-ortho-cresyl phosphate-induced delayed neuropathy. Neurochem. Int. 62 (2013), 965–972.